Table 1 Unweighted patient demographic and baseline clinical characteristics a
From: Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
1-Year | 3-Year | 5-Year | 6-Year | 7-Year | 8-Year | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RLX | ALN | RLX | ALN | RLX | ALN | RLX | ALN | RLX | ALN | RLX | ALN | |
Number of Patients | 23,243 | 72,055 | 9,758 | 24,221 | 3,141 | 6,652 | 1,246 | 2,465 | 650 | 1,053 | 217 | 331 |
63.0 | 64.9 | 63.3 | 65.2 | 63.0 | 65.3 | 62.9 | 64.7 | 62.3 | 64.3 | 60.7 | 63.2 | |
Age (Mean, SD) | (9.5) | (10.7)* | (9.1) | (10.3)* | (8.8) | (10.0)* | (9.0) | (9.8)* | (8.8) | (9.6)* | (7.6) | (9.0)* |
Insurance Plan Typesb | * | * | * | * | ||||||||
Comprehensive | 43.0% | 41.6% | 50.0% | 49.8% | 55.8% | 54.3% | 55.9% | 50.6% | 60.9% | 65.9% | 54.4% | 61.9% |
Preferred provider organization | 35.4% | 33.9% | 31.7% | 29.6% | 25.9% | 23.8% | 21.7% | 19.1% | 19.2% | 14.5% | 20.3% | 11.8% |
Point-of-service plan with capitation | 6.1% | 4.9% | 7.4% | 7.5% | 11.3% | 14.5% | 17.9% | 26.3% | 16.3% | 17.0% | 23.5% | 24.2% |
Point-of-service plan | 8.7% | 6.9% | 7.7% | 5.7% | 5.7% | 4.3% | 4.2% | 3.8% | 3.2% | 2.5% | 1.4% | 1.8% |
Health maintenance organization | 6.1% | 11.7% | 3.0% | 7.0% | 1.1% | 2.9% | 0.3% | 0.2% | 0.3% | 0.1% | 0.5% | 0.3% |
Other/Unknown | 0.6% | 0.9% | 0.2% | 0.3% | 0.1% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Medicare Eligibility | 38.1% | 46.0%* | 41.4% | 49.3%* | 41.8% | 52.1%* | 42.1% | 50.8%* | 39.4% | 49.0%* | 28.1% | 40.8%† |
Urban Residence | 71.8% | 80.5%* | 69.0% | 77.6%* | 64.2% | 71.6%* | 54.3% | 58.8%† | 43.5% | 37.4%† | 28.6% | 16.9%† |
Charlson Comorbidity Index (Mean, SD) | 0.46 (0.95) | 0.54 (1.10)* | 0.44(0.91) | 0.48 (1.02)* | 0.42 (0.87) | 0.44 (0.97) | 0.47 (0.92) | 0.45 (0.98) | 0.44 (0.87) | 0.45 (0.99) | 0.46 (0.87) | 0.51 (1.32) |
BMD Screening | 44.4% | 71.4%* | 40.0% | 69.9%* | 33.4% | 68.5%* | 34.0% | 70.3%* | 31.1% | 70.2%* | 24.9% | 65.0%* |
Pre-period Fracture | 3.9% | 7.7%* | 3.5% | 6.8%* | 2.8% | 5.8%* | 3.4% | 6.2%* | 2.9% | 6.3%† | 3.2% | 5.7% |
Confounding Conditions | ||||||||||||
Hypertension | 26.6% | 25.2%* | 27.4% | 24.9%* | 27.9% | 24.6%* | 28.4% | 25.7% | 28.0% | 24.6% | 29.0% | 21.8% |
Other Cardiovascular Disease | 17.6% | 20.0%* | 17.3% | 19.8%* | 16.5% | 19.6%* | 15.5% | 19.1%† | 14.6% | 19.6%† | 13.4% | 20.2%† |
Metabolic Disorders | 15.6% | 14.9%† | 15.1% | 14.3% | 15.0% | 13.8% | 13.6% | 13.4% | 14.2% | 13.7% | 17.1% | 14.8% |
Diabetes | 9.2% | 7.8%* | 9.8% | 7.0%* | 8.9% | 6.4%* | 8.0% | 6.1%† | 8.3% | 5.9% | 8.8% | 7.3% |
Osteoporosis | 9.4% | 12.9%* | 8.4% | 13.2%* | 7.6% | 13.2%* | 7.2% | 13.8%* | 7.8% | 14.7%* | 9.7% | 16.3%† |
Dyslipidemia | 7.0% | 6.2%* | 6.9% | 6.1%† | 6.8% | 5.7%† | 6.4% | 5.4% | 7.1% | 5.2% | 8.3% | 4.5% |
Rheumatoid arthritis | 1.7% | 2.2%* | 1.5% | 2.2%* | 1.1% | 2.1%* | 1.1% | 2.4%† | 1.2% | 2.4% | 1.4% | 1.8% |
Vasomotor symptoms | 4.1% | 3.5%* | 4.3% | 4.1% | 4.1% | 4.9% | 3.8% | 6.0%† | 3.2% | 7.3%* | 1.4% | 7.9%* |
Ischemic heart disease | 7.5% | 7.5% | 7.4% | 7.6% | 7.3% | 7.6% | 6.7% | 7.2% | 5.4% | 6.6% | 4.1% | 6.9% |
Breast cancer | 4.8% | 6.2%* | 4.5% | 5.8%* | 5.0% | 5.3% | 5.9% | 5.8% | 5.4% | 6.4% | 5.5% | 6.6% |
Reflux | 3.8% | 2.7%* | 3.7% | 2.3%* | 3.6% | 2.5%† | 3.6% | 2.4%† | 3.5% | 2.1% | 2.8% | 2.1% |
Gastritis | 1.8% | 1.4%* | 1.5% | 1.3% | 1.4% | 1.4% | 0.9% | 1.5% | 1.1% | 1.9% | 0.5% | 3.0%† |
Gastric ulcer | 0.4% | 0.2%* | 0.3% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.0% | 0.2% | 0.0% | 0.3% |
Peptic ulcer | 0.1% | 0.1%† | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.1% | 0.3% | 0.2% | 0.5% | 0.0% |
Confounding Medications | ||||||||||||
Glucocorticoids | 17.6% | 19.1%* | 16.4% | 16.7% | 16.0% | 15.2% | 15.0% | 15.8% | 13.1% | 15.6% | 12.0% | 14.8% |
Anticonvulsants | 6.1% | 6.6%† | 5.3% | 5.2% | 4.4% | 4.5% | 4.1% | 3.8% | 4.0% | 2.9% | 3.2% | 2.7% |
Immunosuppressants | 1.7% | 3.1%* | 1.4% | 2.5%* | 1.1% | 2.3%* | 0.7% | 2.2%† | 0.9% | 2.7%† | 0.9% | 3.3% |
Hormone Deprivation Therapy | 2.2% | 3.8%* | 2.0% | 3.5%* | 2.4% | 2.9% | 2.8% | 2.8% | 2.5% | 2.5% | 2.8% | 3.3% |
Estrogen/Hormone Therapy | 43.3% | 29.7%* | 50.3% | 38.2%* | 52.6% | 45.5%* | 38.0% | 43.3%† | 36.5% | 42.4%† | 36.4% | 41.1% |
Pre-period All-cause Healthcare Cost ($, Mean, SD) | 6,954 (18,238) | 7,544 (15,012)* | 5,750 (12,698) | 6,032 (12,196) | 5,154 (9,073) | 5,370 (11,866) | 4,673 (7,807) | 4,970 (9,188) | 4,311 (6,449) | 4,594 (6,652) | 4,358 (7,198) | 4,708 (6,952) |
Pre-period Osteoporosis-related Healthcare Cost ($, Mean, SD) | 268 (1,780) | 484 (2,903)* | 225 (1,394) | 416 (2,738)* | 226 (1,724) | 337 (1,597)† | 243 (2,626) | 327 (1,581) | 134 (573) | 375 (2,121)† | 173 (940) | 319 (1,699) |
Provider closest to Index Prescription | ||||||||||||
Specialist | 38.6% | 37.5%† | 38.9% | 38.8% | 39.4% | 40.5% | 43.1% | 43.0% | 39.8% | 41.2% | 38.7% | 40.5% |
Primary Care | 17.0% | 17.1% | 15.9% | 16.4% | 15.7% | 14.8% | 14.2% | 15.1% | 14.2% | 16.6% | 13.4% | 16.6% |
Other/Unknown | 44.4% | 45.4%† | 45.3% | 44.8% | 44.9% | 44.8% | 42.7% | 42.0% | 46.0% | 42.2% | 47.9% | 42.9% |